FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1891799419> ?p ?o ?g. }

• W1891799419 endingPage "1655" @default.
• W1891799419 startingPage "1649" @default.
• W1891799419 abstract "To compared the response rates and the toxicity of the new antifolate edatrexate (EDX) with that of methotrexate (MTX) in a randomized trial in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCC) and to compare the durations of response and survival.Two hundred seventy-three patients with SCC were randomized to receive either EDX or MTX as a weekly intravenous (IV) bolus injection. Doses of EDX were initially 80 mg/m2/wk, but because of the toxicity, this was later reduced to 70 mg/m2/wk. MTX was administered at a dose of 40 mg/m2/wk throughout. In both arms, two dose increments of 10% were scheduled in case of no toxicity.Of 264 eligible patients, 131 were treated with EDX and 133 with MTX. There were five treatment-related deaths: four on EDX and one on MTX. Overall, toxicity was similar in both arms; however, stomatitis, skin toxicity, and hair loss were more pronounced on the EDX arm. The overall response rate was 21% (six complete responses [CRs] and 21 partial responses [PRs]) for EDX and 16% (nine CRs and 12 PRs) for MTX (P = .392). Responses were mainly seen in patients with locoregional disease. Tumors that originated from the hypopharynx responded poorly in comparison to tumors from other sites. The median duration of response was 6.1 months for EDX and 6.4 months for MTX (log-rank P = .262). There was no difference in overall or progression-free survival. The median survival duration was 6 months on both treatment groups.Both EDX and MTX are moderately active against SCC. In this large phase III study, response rates, time to treatment failure, and overall survival appeared to be similar for both antifolates. However, EDX had more side effects than MTX and therefore cannot be recommended for routine palliative treatment of patients with SCC." @default.
• W1891799419 created "2016-06-24" @default.
• W1891799419 creator A5007067879 @default.
• W1891799419 creator A5011819733 @default.
• W1891799419 creator A5016158055 @default.
• W1891799419 creator A5042731662 @default.
• W1891799419 creator A5045620374 @default.
• W1891799419 creator A5068401090 @default.
• W1891799419 creator A5079463175 @default.
• W1891799419 creator A5080823945 @default.
• W1891799419 creator A5082601500 @default.
• W1891799419 creator A5091091295 @default.
• W1891799419 date "1995-07-01" @default.
• W1891799419 modified "2023-10-14" @default.
• W1891799419 title "Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study." @default.
• W1891799419 cites W1580788756 @default.
• W1891799419 cites W1835228610 @default.
• W1891799419 cites W1926198890 @default.
• W1891799419 cites W1952422131 @default.
• W1891799419 cites W1976065233 @default.
• W1891799419 cites W1979300931 @default.
• W1891799419 cites W1985025279 @default.
• W1891799419 cites W1989339760 @default.
• W1891799419 cites W2007221911 @default.
• W1891799419 cites W2044450235 @default.
• W1891799419 cites W2109261874 @default.
• W1891799419 cites W2132199476 @default.
• W1891799419 cites W2139984188 @default.
• W1891799419 cites W2167805334 @default.
• W1891799419 cites W2256088617 @default.
• W1891799419 cites W2338022921 @default.
• W1891799419 cites W2400544314 @default.
• W1891799419 cites W2475278941 @default.
• W1891799419 doi "https://doi.org/10.1200/jco.1995.13.7.1649" @default.
• W1891799419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7602354" @default.
• W1891799419 hasPublicationYear "1995" @default.
• W1891799419 type Work @default.
• W1891799419 sameAs 1891799419 @default.
• W1891799419 citedByCount "71" @default.
• W1891799419 countsByYear W18917994192012 @default.
• W1891799419 countsByYear W18917994192014 @default.
• W1891799419 countsByYear W18917994192015 @default.
• W1891799419 countsByYear W18917994192016 @default.
• W1891799419 countsByYear W18917994192018 @default.
• W1891799419 countsByYear W18917994192019 @default.
• W1891799419 countsByYear W18917994192020 @default.
• W1891799419 countsByYear W18917994192022 @default.
• W1891799419 crossrefType "journal-article" @default.
• W1891799419 hasAuthorship W1891799419A5007067879 @default.
• W1891799419 hasAuthorship W1891799419A5011819733 @default.
• W1891799419 hasAuthorship W1891799419A5016158055 @default.
• W1891799419 hasAuthorship W1891799419A5042731662 @default.
• W1891799419 hasAuthorship W1891799419A5045620374 @default.
• W1891799419 hasAuthorship W1891799419A5068401090 @default.
• W1891799419 hasAuthorship W1891799419A5079463175 @default.
• W1891799419 hasAuthorship W1891799419A5080823945 @default.
• W1891799419 hasAuthorship W1891799419A5082601500 @default.
• W1891799419 hasAuthorship W1891799419A5091091295 @default.
• W1891799419 hasBestOaLocation W18917994192 @default.
• W1891799419 hasConcept C121608353 @default.
• W1891799419 hasConcept C126322002 @default.
• W1891799419 hasConcept C141071460 @default.
• W1891799419 hasConcept C168563851 @default.
• W1891799419 hasConcept C2776530083 @default.
• W1891799419 hasConcept C2776694085 @default.
• W1891799419 hasConcept C2778397455 @default.
• W1891799419 hasConcept C2779051857 @default.
• W1891799419 hasConcept C2781059491 @default.
• W1891799419 hasConcept C2781382166 @default.
• W1891799419 hasConcept C29730261 @default.
• W1891799419 hasConcept C2994460389 @default.
• W1891799419 hasConcept C31760486 @default.
• W1891799419 hasConcept C509974204 @default.
• W1891799419 hasConcept C71924100 @default.
• W1891799419 hasConcept C90924648 @default.
• W1891799419 hasConceptScore W1891799419C121608353 @default.
• W1891799419 hasConceptScore W1891799419C126322002 @default.
• W1891799419 hasConceptScore W1891799419C141071460 @default.
• W1891799419 hasConceptScore W1891799419C168563851 @default.
• W1891799419 hasConceptScore W1891799419C2776530083 @default.
• W1891799419 hasConceptScore W1891799419C2776694085 @default.
• W1891799419 hasConceptScore W1891799419C2778397455 @default.
• W1891799419 hasConceptScore W1891799419C2779051857 @default.
• W1891799419 hasConceptScore W1891799419C2781059491 @default.
• W1891799419 hasConceptScore W1891799419C2781382166 @default.
• W1891799419 hasConceptScore W1891799419C29730261 @default.
• W1891799419 hasConceptScore W1891799419C2994460389 @default.
• W1891799419 hasConceptScore W1891799419C31760486 @default.
• W1891799419 hasConceptScore W1891799419C509974204 @default.
• W1891799419 hasConceptScore W1891799419C71924100 @default.
• W1891799419 hasConceptScore W1891799419C90924648 @default.
• W1891799419 hasIssue "7" @default.
• W1891799419 hasLocation W18917994191 @default.
• W1891799419 hasLocation W18917994192 @default.
• W1891799419 hasLocation W18917994193 @default.
• W1891799419 hasOpenAccess W1891799419 @default.
• W1891799419 hasPrimaryLocation W18917994191 @default.
• W1891799419 hasRelatedWork W1559475713 @default.

• next